Nodal promotes the generation of M2-like macrophages and downregulates the expression of IL-12

European Journal of Immunology

Volumn 44, Issue 1, 2014, Pages 173-183

  Wang, Xian Feng ^a   Wang, Hong Sheng ^a   Zhang, Fan ^a   Guo, Qiang ^a   Wang, Hao ^a   Wang, Ke Fang ^b   Zhang, Ge ^a   Bu, Xian Zhang ^a   Cai, Shao Hui ^c   Du, Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

Cancer therapy; IL 12; M2 like macrophage; Nodal; TAMs

Indexed keywords

INTERLEUKIN 12; NODAL SIGNALING PROTEIN; PROTEIN M2; RECOMBINANT PROTEIN; PROTEIN NODAL; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERTANT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CARCINOGENESIS; GENETICS; IMMUNOLOGY; METABOLISM; MIXED LYMPHOCYTE CULTURE; NEOPLASMS; TH2 CELL;

ANIMALS; BONE MARROW CELLS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; INTERLEUKIN-12; LYMPHOCYTE CULTURE TEST, MIXED; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; NEOPLASMS; NODAL PROTEIN; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TH2 CELLS;

EID: 84892466847     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343535     Document Type: Article

References (50)

1. Gordon, S. and Taylor, P. R., Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005. 5: 953-964.
2. Biswas, S. K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., Bottazzi, B. et al., A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κ B and enhanced IRF-3/STAT1 activation). Blood 2006. 107: 2112-2122.
3. Gordon, S., Alternative activation of macrophages. Nat. Rev. Immunol. 2003. 3: 23-35.
4. Zabuawala, T., Taffany, D. A., Sharma, S. M., Merchant, A., Adair, B., Srinivasan, R., Rosol, T. J. et al., An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res. 2010. 70: 1323-1333.
5. Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., Hussell, T. et al., IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011. 12: 231-238.
6. Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M. et al., Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008. 18: 349-355.
7. Chen, J. J., Lin, Y. C., Yao, P. L., Yuan, A., Chen, H. Y., Shun, C. T., Tsai, M. F. et al., Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 2005. 23: 953-964.
8. Hao, N. B., Lu, M. H., Fan, Y. H., Cao, Y. L., Zhang, Z. R. and Yang, S. M., Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012. 2012: 948098.
9. Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., Sakoda, M. et al., Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 2011. 167: e211-e219.
10. Wu, A., Wei, J., Kong, L. Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R. et al., Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro. Oncol. 2010. 12: 1113-1125.
11. Porrata, L. F., Ristow, K., Colgan, J. P., Habermann, T. M., Witzig, T. E., Inwards, D. J., Ansell, S. M. et al., Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012. 97: 262-269.
12. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004. 4: 11-22.
13. Mantovani, A. and Sica, A., Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010. 22: 231-237.
14. Pollard, J. W., Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004. 4: 71-78.
15. Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W. J., Huhn, R. D. et al., CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011. 331: 1612-1616.
16. Shiao, S. L., Ganesan, A. P., Rugo, H. S. and Coussens, L. M., Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011. 25: 2559-2572.
17. Tang, X., Mo, C., Wang, Y., Wei, D. and Xiao, H., Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2012. 138: 93-104.
18. Mantovani, A., Germano, G., Marchesi, F., Locatelli, M. and Biswas, S. K., Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur. J. Immunol. 2011. 41: 2522-2525.
19. Brennan, J., Norris, D. P. and Robertson, E. J., Nodal activity in the node governs left-right asymmetry. Genes Dev. 2002. 16: 2339-2344.
20. Mesnard, D., Guzman-Ayala, M. and Constam, D. B., Nodal specifies embryonic visceral endoderm and sustains pluripotent cells in the epiblast before overt axial patterning. Development 2006. 133: 2497-2505.
21. James, D., Levine, A. J., Besser, D. and Hemmati-Brivanlou, A., TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005. 132: 1273-1282.
22. Smith, J. R., Vallier, L., Lupo, G., Alexander, M., Harris, W. A. and Pedersen, R. A., Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. Dev. Biol. 2008. 313: 107-117.
23. Schier, A. F., Nodal signaling in vertebrate development. Annu. Rev. Cell Dev. Biol. 2003. 19: 589-621.
24. Topczewska, J. M., Postovit, L. M., Margaryan, N. V., Sam, A., Hess, A. R., Wheaton, W. W., Nickoloff, B. J. et al., Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med. 2006. 12: 925-932.
25. Lawrence, M. G., Margaryan, N. V., Loessner, D., Collins, A., Kerr, K. M., Turner, M., Seftor, E. A. et al., Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate 2011. 71: 1198-1209.
26. De Silva, T., Ye, G., Liang, Y. Y., Fu, G., Xu, G. and Peng, C., Nodal promotes glioblastoma cell growth. Front Endocrinol. 2012. 3: 59-1-6.
27. Hendrix, M. J., Seftor, E. A., Seftor, R. E., Kasemeier-Kulesa, J., Kulesa, P. M. and Postovit, L. M., Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 2007. 7: 246-255.
28. Lee, C. C., Jan, H. J., Lai, J. H., Ma, H. I., Hueng, D. Y., Lee, Y. C., Cheng, Y. Y. et al., Nodal promotes growth and invasion in human gliomas. Oncogene 2010. 29: 3110-3123.
29. Hueng, D. Y., Lin, G. J., Huang, S. H., Liu, L. W., Ju, D. T., Chen, Y. W., Sytwu, H. K. et al., Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. J. Neurooncol. 2011. 104: 21-31.
30. Strizzi, L., Hardy, K. M., Margaryan, N. V., Hillman, D. W., Seftor, E. A., Chen, B., Geiger, X. J. et al., Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res. 2012. 14: R75-1-12.
31. Quail, D. F., Siegers, G. M., Jewer, M. and Postovit, L. M., Nodal signalling in embryogenesis and tumourigenesis. Int. J. Biochem. Cell Biol. 2013. 45: 885-898.
32. Sierra-Filardi, E., Puig-KrÖger, A., Blanco, F. J., Nieto, C., Bragado, R., Palomero, M. I., Bernabéu, C. et al., Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory. Blood 2011. 117: 5092-5101.
33. McAllister, J. C., Zhan, Q., Weishaupt, C., Hsu, M. Y. and Murphy, G. F., The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J. Cutan. Pathol. 2010. 37(Suppl 1): 19-25.
34. Donahue, T. R. and Dawson, D. W., Nodal/Activin signaling: a novel target for pancreatic cancer stem cell therapy. Cell Stem Cell. 2011. 9: 383-384.
35. Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J. et al., SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002. 62: 65-74.
36. Verreck, F. A., de Boer, T., Langenberg, D. M., van der Zanden, L. and Ottenhoff, T. H., Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J. Leukoc. Biol. 2006. 79: 285-293.
37. Leidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M. et al., M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J. Immunol. 2009. 182: 4415-4422.
38. Duff, M. D., Mestre, J., Maddali, S., Yan, Z. P., Stapleton, P. and Daly, J. M., Analysis of gene expression in the tumor-associated macrophage. J. Surg. Res. 2007. 142: 119-128.
39. Sica, A., Schioppa, T., Mantovani, A. and Allavena, P., Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006. 42: 717-727.
40. Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Plüddemann, A., Charles, K. et al., Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 2006. 176: 5023-5032.
41. Kuang, D. M., Wu, Y., Chen, N. N., Cheng, J. S., Zhuang, S. M. and Zheng, L. M., Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 2007. 110: 587-595.
42. Bennett, J. T., Stickney, H. L., Choi, W. Y., Ciruna, B., Talbot, W. S. and Schier, A. F., Maternal nodal and zebrafish embryogenesis. Nature 2007. 450: E1-E2; discussion E2-E4.
43. Strizzi, L., Hardy, K. M., Kirsammer, G. T., Gerami, P. and Hendrix, M. J., Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab. Invest. 2011. 91: 819-824.
44. Fang, R., Zhang, G., Guo, Q., Ning, F., Wang, H., Cai, S. and Du, J., Nodal promotes aggressive phenotype via snail-mediated epithelial-mesenchymal transition in murine melanoma. Cancer Lett. 2013. 333: 66-75.
45. Watkins, S. K., Egilmez, N. K., Suttles, J. and Stout, R. D., IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 2007. 178: 1357-1362.
46. Liu, G. and Yang, H., Modulation of macrophage activation and programming in immunity. J. Cell Physiol. 2012. 228: 502-512.
47. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. and Sica, A., Macrophage polarization:tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002. 23: 549-555.
48. Zeng, J., Cai, S., Yi, Y., He, Y., Wang, Z., Jiang, G., Li, X. et al., Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2, 3-dioxygenase inhibitor 1-methyl tryptophan. Cancer Res. 2009. 69: 3963-3970.
49. Jiang, G. M., He, Y. W., Fang, R., Zhang, G., Zeng, J., Yi, Y. M., Zhang, S. et al., Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels. Int. J. Biochem. Cell Biol. 2010. 42: 1840-1846.
50. Daigneault, M., Preston, J. A., Marriott, H. M., Whyte, M. K. B. and Dockrell, D. H., The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 2010. 5: e8668.